Pharming Group N.V.
PHARDrugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Oct 2026
Market Overview
Stock performance and key metrics
3 upcoming, 2 past
How PHAR's past catalysts played out
Leniolisib
PIDs Linked to PI3K
i.v. recombinant human C1 inhibitor
Genetic Disorders
recombinant human C1 inhibitor
Hereditary Angioedema
rhC1INH
Hereditary Angioedema
Ruconest
Confirmed Coronavirus Disease
KL1333
Primary Mitochondrial Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Leniolisib | Phase 3 | PIDs Linked to PI3K | - | - |
i.v. recombinant human C1 inhibitor | Phase 3 | Genetic Disorders | - | - |
recombinant human C1 inhibitor | Phase 3 | Hereditary Angioedema | - | - |
rhC1INH | Phase 3 | Hereditary Angioedema | - | - |
Ruconest | Phase 2 | Confirmed Coronavirus Disease | - | - |
KL1333 | Phase 2 | Primary Mitochondrial Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pharming Group N.V.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Pharming Group N.V.'s (PHAR) pipeline across Phase 3, Phase 2. Its lead program is Leniolisib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharming Group N.V.'s next FDA catalyst?→
Pharming Group N.V.'s (PHAR) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHAR biotech catalysts?→
Add PHAR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharming Group N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.